



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at [www.bccancer.bc.ca](http://www.bccancer.bc.ca) and according to acceptable standards of care

PROTOCOL CODE: LYCLLCHLR Page 1 of 4

<b>DOCTOR'S ORDERS</b>			Ht _____ cm	Wt _____ kg	BSA _____ m <sup>2</sup>
<b>REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy &amp; Alert Form</b>					
<b>DATE:</b>	<b>To be given:</b>	<b>Cycle #:</b>			
<b>Date of Previous Cycle:</b>					
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> <b>CBC &amp; Diff, Platelets</b> day of treatment May proceed with doses as written if within 96 hours <b>ANC greater than or equal to 1.2 x 10<sup>9</sup>/L, Platelets greater than or equal to 80 x 10<sup>9</sup>/L</b> Dose modification for: <input type="checkbox"/> <b>Hematology</b> <input type="checkbox"/> <b>Other Toxicity</b> _____ <b>Proceed with treatment based on blood work from</b> _____					
<b>TREATMENT:</b>					
<b>Schedule 1:</b>					
chlorambucil <b>0.4 mg/kg</b> x Wt = _____ mg PO on <b>day 1</b> and <b>day 15</b>					
<input type="checkbox"/> Dose Modification: _____ mg/kg x Wt = _____ mg					
Round each dose to the nearest 2 mg.					
<b>OR</b>					
<b>Schedule 2:</b>					
chlorambucil <b>10 mg/m<sup>2</sup></b> x BSA = _____ mg PO on <b>days 1 to 7</b>					
<input type="checkbox"/> Dose Modification: _____ % = _____ mg/m <sup>2</sup> x BSA = _____ mg					
Round each dose to the nearest 2 mg. (May divide dose into 2-3 subdoses each day to improve tolerance)					
NOTE: Chlorambucil may be given without ritUXimab after cycle 6.					
<b>(Continued on Page 2)</b>					
<b>DOCTOR'S SIGNATURE:</b>				<b>SIGNATURE:</b>	
				<b>UC:</b>	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at [www.bccancer.bc.ca](http://www.bccancer.bc.ca) and according to acceptable standards of care

**PROTOCOL CODE: LYCLLCHLR** Page 2 of 4

DATE:

**\*\*Have Hypersensitivity Reaction Tray and Protocol Available\*\***

**PREMEDICATIONS:** Patient to take own supply. RN/Pharmacist to confirm\_\_\_\_\_.

**For intravenous riTUXimab infusion:**

**diphenhydrAMINE 50 mg** PO prior to **riTUXimab IV** and then q 4 h if IV infusion exceeds 4 h

**acetaminophen 650 mg to 975 mg** PO prior to **riTUXimab IV** and then q 4 h if IV infusion exceeds 4 h

**For subcutaneous riTUXimab injection:**

**diphenhydrAMINE 50 mg** PO prior to **riTUXimab subcutaneous**

**acetaminophen 650 mg to 975 mg** PO prior to **riTUXimab subcutaneous**

Other

**TREATMENT: (continued)**

**CYCLE #1:**

**riTUXimab (first dose) 375 mg/m<sup>2</sup> x BSA = \_\_\_\_\_ mg**

IV in 250 to 500 mL NS within 72 hours after Day 1 of chlorambucil.

Pharmacy to select riTUXimab IV brand as per Provincial Systemic Therapy Policy III-190

Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date
riTUXimab		

Start at 50 mg/h. After 1 hour, increase rate by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs.

For the first dose, patients are to be under constant visual observation during all dose increases and for 30 minutes after infusion completed. Vital signs are not required, unless symptomatic.

(Continued on Page 3)

**DOCTOR'S SIGNATURE:**

**SIGNATURE:**

**UC:**

DATE:

**TREATMENT: (Continued)**

**riTUXimab for Cycle 2 and subsequent treatments:**

Patient tolerated a full dose of IV riTUXimab (no severe reactions requiring early termination) and can proceed to subcutaneous riTUXimab:

**riTUXimab subcut (RITUXAN SC) 1600 mg (fixed dose in 13.4 mL) subcutaneously** into abdomen over 7 minutes on day 1 of chlorambucil. Observe for 15 minutes after administration.

NB: During treatment with subcutaneous riTUXimab, administer other subcutaneous drugs at alternative injection sites whenever possible.

OR

Patient did not tolerate a full dose of IV riTUXimab (experienced severe reactions requiring early termination) in the previous treatment and will continue with IV riTUXimab for this cycle:

**riTUXimab 500 mg/m<sup>2</sup> x BSA = \_\_\_\_\_ mg**

IV in 250 to 500 mL NS on Day 1 or 2 whenever possible, but not later than 72 hours after Day 1 of chlorambucil

Pharmacy to select riTUXimab IV brand as per Provincial Systemic Therapy Policy III-190

Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date
riTUXimab		

Infuse 50 mL (or 100 mL of 500 mL bag) of the dose over 30 minutes, then infuse the remaining 200 mL (or 400 mL of 500 mL bag) over 1 hour. (total infusion time = 1 hour 30 min)

If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician. Constant visual observation is not required.

**DOCTOR'S SIGNATURE:**

**SIGNATURE:**

**UC:**



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at [www.bccancer.bc.ca](http://www.bccancer.bc.ca) and according to acceptable standards of care

**PROTOCOL CODE: LYCLLCHLR** Page 4 of 4

<b>Date:</b>	
<b>RETURN APPOINTMENT ORDERS</b>	
<input type="checkbox"/> Return in <b>four</b> weeks for Doctor and Cycle _____. (Book chemo for riTUXimab treatment only.)	
<input type="checkbox"/> RTC in <b>four</b> weeks for Doctor and Cycle _____. (No riTUXimab treatment)	
<input type="checkbox"/> Last Cycle. Return in _____ week(s).	
<b>CBC &amp; Diff, Platelets</b> prior to each cycle	
<input type="checkbox"/> <b>Other tests:</b>	
<input type="checkbox"/> <b>Consults:</b>	
<input type="checkbox"/> <b>See general orders sheet for additional requests.</b>	
<b>DOCTOR'S SIGNATURE:</b>	<b>SIGNATURE:</b> <b>UC:</b>